Brooklyn ImmunoTherapeutics (BTX)

Brooklyn ImmunoTherapeutics (BTX) is a clinical-stage biopharmaceutical company committed to creating a world where patients and families with high unmet medical needs have access to effective treatments. We are pioneers in using the latest technologies such as synthetic mRNA, cellular reprogramming, gene editing, and complex human-derived mixed cytokines. These advances fuel our ongoing programs, including iPSC-derived MSC (iMSC), gene-edited iMSC, and in vivo gene editing. Additionally, we have developed the IRX-2 immuno-therapy, which is approaching the conclusion of its Phase2B study. The BTX team is diverse in its backgrounds and experience and federated around the use of science and technology to advance transformative therapies to meet the needs of patients.